利妥昔单抗联合化疗治疗弥漫性大B细胞淋巴瘤临床观察

<正>弥漫性大B细胞淋巴瘤(DLBCL)临床进展较为迅速,属于侵袭性的恶性淋巴瘤,发病年龄偏大,多见于50~60岁的患者,对化疗较为敏感,传统治疗采用环磷酰胺+多柔比星+长春新碱+地塞米松(CHOP)方案进行化疗,患者病情容易复发,并且易产生耐药性,长期存活率不高。而利妥昔单抗联合化疗应用于DLBCL的治疗,改善了DLBCL的疗效及预后。本研究对比利妥昔单抗联合CTOP(R-CTOP)方案化疗与单用CTOP方案进     

利妥昔单抗治疗老年B细胞非霍奇金淋巴瘤11例临床观察

目的观察利妥昔单抗联合化疗对老年人C020阳性B细胞非霍奇金淋巴瘤的临床疗效和不良反应。方法11例经病理及免疫组化证实的CD20阳性的B细胞非霍奇金淋巴瘤患者,每疗程化疗前即第1天给予利妥昔单抗375mg／m^2,第2天开始化疗。采用CHOP方案化疗．每21～28天重复疗程,至少4个疗程。结果总有效率为8／11,完全缓解4／11,部分缓解4／11,稳定2／11,进展1／11;主要不良反应是胃肠道反应、骨髓抑制、脱发等,少数病人出现畏寒、发热、皮肤潮红、血压升高、胸闷等利妥昔单抗输注相关反应,1例患者继发出现口唇疱疹。结论利妥昔单抗联合化疗治疗老年B细胞性淋巴瘤具有良好的临床疗效,其不良反应可为老年患者接受,利妥昔单抗联合CHOP方案适于老年淋巴瘤患者的治疗。     

老年弥漫大B细胞淋巴瘤50例患者的临床特征和预后分析

目的 探讨老年弥漫大B细胞淋巴瘤（DLBCL）患者的临床特征及预后因素。方法 回顾性分析2010年1月至2013年1月,第四军医大学西京医院血液内科收治的50例年龄≥70岁的老年DLBCL患者,收集整理年龄、Ann-Arbor分期、B症状、国际预后指数（IPI）、乳酸脱氢酶（LDH）、β2?微球蛋白、Ki-67等资料进而分析临床特点;采用Kaplan-Meier法进行生存分析,并进行单因素分析评估预后。结果 50例初发老年DLBCL患者中,60%患者为Ⅲ～Ⅳ期,54% IPI评分为3～5分,52%有B症状,75%原发部位为结外。在老年患者中,调整剂量的化疗疗效优于放疗及对症支持治疗。利妥昔单抗联合剂量调整化疗（R-CHOP）组完全缓解（CR）率优于不包括利妥昔单抗的剂量调查化疗（CHOP/COP）组。患者中位生存时间为 8个月,1、2、3年总生存率分别为48.5%、30.8%、11.5%。生存分析发现Ki-67对患者生存有显著的影响,尤其是Ki-67＞80%患者预后差。结论 老年患者以疾病分期晚,易合并其他系统疾病,生存期短为特征,具有更高的DLBCL发病率,Ki-67是一个重要的不良预后指标。R-CHOP方案可明显提高CR率,并且足够疗程的化疗将显著改善超高龄患者的生存期。     

原发肾上腺弥漫大B细胞淋巴瘤5例临床及病理特征分析

目的:报道5例原发肾上腺弥漫大B细胞淋巴瘤(DLBCL)的临床以及病理特点,提高对原发肾上腺DLBCL的认识及诊治水平。方法:回顾性分析在我院诊治的5例原发肾上腺DLBCL患者的临床及病理资料。结果:5例原发肾上腺DLBCL,其中4例为老年男性;临床多以腰痛或腹痛为首发表现,5例患者均伴有B症状,4例伴有乳酸脱氢酶升高,IPI积分多为中高危;3例患者伴有肾上腺皮质功能不全,其中2例需要糖皮质激素替代治疗;影像学均为双侧肾上腺肿块,超声或CT引导下穿刺病理确诊;病理4例呈现双表达DLBCL,活化B细胞来源;未见骨髓受累患者。原发肾上腺DLBCL采用包含利妥昔单抗的联合化疗疗效较理想,但停药易复发,应用来那度胺或沙利度胺维持治疗可能可以减少复发;治疗需要兼顾中枢神经系统淋巴瘤的预防,包括大剂量甲氨蝶呤或来那度胺预防。结论:本研究结果提示发现双侧肾上腺占位需要警惕原发肾上腺淋巴瘤,确诊需要活检病理证实;原发肾上腺DLBCL治疗建议含有利妥昔单抗的联合化疗,同时给予中枢淋巴瘤预防,联合化疗结束后建议维持治疗1～2年有助于减少复发。     

弥漫大B细胞淋巴瘤预后新指标

弥漫大B 细胞淋巴瘤(DLBCL) 是一种高度异质性的疾病, 临床表现和预后差异较大。经典的预后评价系统 国际预后指数(IPI) 评分是基于年龄、疾病分期和体能状态等简单的临床参数, 由于其自身的局限性和利妥昔单抗 纳入DLBCL 的一线治疗, 经典指标的预后价值存在争议。随着对于DLBCL 认识的深入和新技术的出现, 越来越 多新DLBCL 预后评价指标涌现, 这些新指标的出现将更加有利于丰富和完善DLBCL 的预后评价系统, 以利于更 好的为患者提供精确的诊断分层和个体化治疗。     

19例原发骨淋巴瘤临床病理特点及预后分析

目的:分析原发骨淋巴瘤(PBL)的临床病理特征及预后相关因素。方法:回顾性分析19例PBL患者的临床病理资料,分析总结其临床病理特征及预后因素。结果:119例患者中位发病年龄为51(15~78)岁。主要病理类型为弥漫大B细胞淋巴瘤,共15例(78.9%),其中非生发中心型9例(60.0%),生发中心型6例(40.0%)。首发症状最常见为骨痛或活动障碍(18/19,94.7%)。单病灶骨受累14例(73.7%),多病灶骨受累5例(26.3%)。单病灶受累最常见部位是股骨,有4例(28.6%),其次为骨盆3例(21.4%)、脊椎3例(21.4%)。Ann Arbor临床分期Ⅰ~Ⅱ期占52.6%,Ⅳ期占47.4%。15例行PET-CT检查,其中Ⅳ期7例(46.7%)。217例接受联合化疗,另2例仅接受手术剔除修复治疗。近期疗效显示9例(52.9%)达完全缓解(CR),7例(41.2%)达部分缓解,1例(5.9%)疾病进展。3年龄与CR率有关(P0.05),而性别、临床分期、IPI评分、肿瘤细胞起源、血清β2-微球蛋白、乳酸脱氢酶、铁蛋白水平及是否应用利妥昔单抗体与CR率无明显相关性(P0.05)。中位随访15(2~60)个月,其中16例存活,2例死亡,1例失访;中位无进展时间为16(4~60)个月。年龄及应用利妥昔单抗是重要的预后因素,初始诱导化疗CR患者可能总生存更佳,但差异无统计学意义(P=0.093);肿瘤细胞起源与总生存无关。结论:PBL主要病理类型为弥漫大B细胞淋巴瘤,年龄与治疗CR率相关,年龄及联合利妥昔单抗治疗是重要的预后相关因素。     

R-CHOP方案治疗侵袭性B细胞淋巴瘤15例

侵袭性B细胞淋巴瘤是一类最常见的非霍奇金淋巴瘤(NHL),而且大部分起源于B淋巴细胞并表达CD20抗原,对常规化疗、放疗较为敏感,但容易复发或耐药。有学者认为,利妥昔单克隆抗体(又名美罗华,上海罗氏制药有限公司,国药准字J20040111)联合化疗治疗侵袭性B细胞淋巴瘤疗效好〔1,2〕。本文比较利妥昔单克隆抗体联合CHOP方案与单用CHOP方案治疗侵袭性B细胞淋巴瘤的疗效。     

十二指肠型滤泡性淋巴瘤4例临床特征分析并文献复习

总结4例十二指肠型滤泡性淋巴瘤(duodenal type follicular lymphoma, DFL)患者的临床表现、病理学特征、治疗及预后。回顾性分析青岛大学附属医院2018年1月至2022年2月确诊并治疗的4例DFL患者的临床资料,并进行相关文献复习。4例患者中男3例,女1例;中位年龄52.5(38～70)岁。4例患者均行内镜检查,病变部位均位于十二指肠降段。1例患者合并幽门螺杆菌感染。治疗方面,2例患者随访观察,1例患者以R-COP方案作为一线化疗方案,应用4个疗程后改为利妥昔单抗单药治疗,1例患者采用奥妥珠单抗治疗。1例患者复查胃镜显示十二指肠降部仍有病变,2例患者疾病未进展,1例患者疾病完全缓解。DFL是一种惰性的、进展缓慢的淋巴瘤,大多数DFL是在检查中偶然发现,多数患者临床症状不明显,部分患者可能出现腹部不适。该疾病总体预后较好,无进展生存期和总生存期高。目前尚无关于DFL最佳治疗方案的明确建议,治疗选择包括随访观察、利妥昔单抗单药治疗以及联合化疗和放疗等。     

原发性胃肠道弥漫大B细胞淋巴瘤的预后因素分析

目的 :探讨原发性胃肠道弥漫大B细胞淋巴瘤(PGI-DLBCL)的临床特点、免疫表型及治疗方案与预后的关系。方法:收集我院2000年4月至2014年6月诊治的91例PGI-DLBCL患者的临床资料,对其临床特征、治疗方案、免疫分型以及疗效进行回顾性分析。结果:随访时间为3~166个月,中位随访时间49个月。91例PGI-DLBCL患者中,男女比例为1.22∶1,中位年龄57(17~79)岁。Ann Arbor分期Ⅰ~Ⅱ期49例(53.8%),Ⅲ~Ⅳ期42例(46.2%);血清乳酸脱氢酶(LDH)正常者75例(82.4%),升高者16例(17.6%);国际预后指数(IPI)低/低中危患者73例(80.2%),中/中高危患者18例(19.8%);生发中心B细胞(GCB)患者22例(34.9%),非GCB(non GCB)患者41例(65.1%);采用CHOP(环磷酰胺、长春地辛、表柔比星、甲泼尼龙)方案治疗的55例(60.4%),利妥昔单抗联合CHOP方案化学治疗(化疗)36例(39.6%),5年总生存(OS)率分别为75.5%、95.7%。单因素分析结果显示IPI、Ann Arbor临床分期、LDH水平、免疫分型以及是否联合利妥昔单抗化疗对生存率有显著影响(均P     

套细胞淋巴瘤27例临床特征及生存预后分析

目的探讨套细胞淋巴瘤(MCL)的临床特点、治疗及预后因素。方法回顾分析2000年4月至2008年12月中国医学科学院血液病医院27例MCL患者的临床资料及不同治疗方案疗效及预后因素。结果27例患者中位发病年龄59岁,男女比例2.4∶1,其中88.9%骨髓侵犯、临床分期为Ⅳ期,59.3%脾大,33.3%B症状,11.1%肝大,44.4%乳酸脱氢酶(LDH)升高,21例染色体检查结果中7例(33.3%)伴附加染色体异常。20例外院诊断结果中,15例(75%)误诊。24例初治患者中,8例利妥昔单抗联合化疗者完全缓解(CR/CRu)、3年总存活(OS)、无进展生存(PFS)率显著高于常规化疗组(分别为87.5%对31.3%,87.5%对24.1%,70.0%对26.9%;P均<0.05)。预后分析显示,年龄>60岁、B症状、肝大、乳酸脱氢酶(LDH)升高、血红蛋白<110g/L、白蛋白<40g/L及染色体异常≥4种为预后不良因素,而骨髓侵犯、脾大、临床分期对预后无显著影响。伴复杂染色体异常者预后极差,中位生存仅3.5个月。结论中国MCL误诊率高,其临床特点与国外报道类似。利妥昔单抗联合化疗可明显提高CR/CRu,并改...     

乳腺原发恶性淋巴瘤的诊断及治疗方法探讨

目的探讨乳腺原发恶性淋巴瘤(PBL)的临床特点及诊断、治疗方法。方法对经病理检查证实的11例女性PBL患者的临床表现、检查及治疗方法、预后等进行分析。结果11例均经手术或穿刺活检取标本，组织学及免疫组织化学检查证实为非霍奇金氏淋巴瘤(NHL)，B细胞来源10例、T细胞来源1例，弥漫性大B细胞型占54．5％(6／11)。10例分别接受乳腺肿瘤根治术或改良根治术或肿块切除术。均辅以化疗和放射治疗。首程治疗后7例获得局部控制。全组无病生存期4～49个月(中位生存期12个月)，总生存期15～110个月(中位30个月)。结论PBL的确诊依靠病理组织学和免疫组织化学检查。治疗应包括局部手术、放射治疗和化疗的综合治疗。     

Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis

Gastric mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B cell lymphoma (DLBCL) show a spectrum of disease characterized by varying proportions of low-grade and high-grade components. While the natural history and optimum treatment for low-grade gastric MALT lymphoma and DLBCL is well established, the prognosis and optimal treatment of patients with both low- and high-grade components is not well established. The purpose of our study was to evaluate the clinical characteristics, survival outcomes, and prognostic factors of patients with gastric MALT lymphoma and gastric DLBCL. A retrospective review of patients with gastric MALT lymphoma, gastric DLBCL, or MALT lymphoma with a high-grade component treated at our centers from 1994 to 2006 was performed. Patients were divided into three categories: “pure MALT lymphoma,” “MALT lymphoma with high-grade component” (mixed), and “pure DLBCL.” Seventy-six patients were included in our study—26 with pure MALT, 22 with MALT with high-grade component (“mixed”), and 28 with pure DLBCL. Pure MALT lymphoma and mixed lymphoma patients had similar clinical characteristics, whereas pure DLBCL patients had less favorable disease characteristics with significantly poorer performance status, higher number of extranodal sites of disease, higher stage, and larger proportion of bone marrow involvement and international prognostic index (IPI) scores compared with mixed lymphoma. The majority of mixed lymphoma (72.7%) and DLBCL patients (71.4%) were treated with chemotherapy. Of patients receiving chemotherapy, a higher proportion of mixed lymphoma and DLBCL patients received anthracycline-based combination chemotherapy regimens compared with MALT lymphoma (73% vs 71% vs 8%) whereas the proportion of mixed lymphoma and DLBCL patients was similar (p = 0.919). At a median follow-up of 37 months, the 5-year overall survival was 66.9%. The 5-year overall survival was 78% for MALT lymphoma, 84% for mixed lymphoma, and 45% for DLBCL. On univariate analysis, DLBCL histology, age, performance status, serum albumin, lactate dehydrogenase, bone marrow, number of extranodal sites, stage, and IPI score were prognostic for inferior survival. On multivariate analysis, DLBCL histology remained significantly prognostic for inferior survival, independent of chemotherapy regimen (hazard ratio (HR) 6.66, 95% confidence interval (CI) 2.01–21.41, p = 0.001). Mixed histology was not prognostic for inferior survival (HR 1.13, 95% CI 0.28–4.54, p = 0.868). Other factors prognostic for inferior survival were serum albumin <37 g/L (HR 3.22, 95% CI 1.11–13.22, p = 0.034) and treatment with non-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy (HR 4.89, 95% CI 1.67–14.36, p = 0.004). In conclusion, the clinical characteristics of mixed histology MALT lymphoma are similar to low-grade MALT lymphoma and significantly different from pure DLBCL. The prognosis of mixed histology MALT lymphoma is significantly better than pure DLBCL, independent of IPI and chemotherapy regimen, and pure DLBCL histology is independently prognostic of inferior survival outcome.     

胃肠道淋巴瘤放疗进展

原发胃肠道淋巴瘤是最常见的结外非霍奇金淋巴瘤。胃肠道淋巴瘤为异质性的肿瘤,弥漫大B细胞淋巴瘤和粘膜相关淋巴瘤是最常见的病理类型,放疗在不同部位和病理类型的淋巴瘤治疗中地位不同。原发胃淋巴瘤接受保留胃功能的治疗可取得良好预后,弥漫大B细胞淋巴瘤化疗后（包括完全缓解）接受放疗可提高局控率和生存率,美罗华时代大肿块患者仍需要接受放疗以提高局部控制率。早期胃MALT淋巴瘤抗HP失败后,接受单纯放疗即可取得良好的预后。原发肠道侵袭性淋巴瘤的治愈手段仍为外科治疗,惰性淋巴瘤亦可选择放疗。     

骨原发性淋巴瘤继发中枢神经系统浸润1例病例报告及文献复习

目的:探讨骨原发性淋巴瘤(primary bone lymphoma,PBL)继发中枢神经系统(CNS)浸润的主要临床特点、诊断及治疗。方法:分析我科收治的1例弥漫大B细胞性PBL继发CNS浸润患者的临床表现及相关检查结果,治疗方法,并复习相关文献。结果:本例患者为老年男性,主要临床表现为骨痛,经PET/CT、骨髓象、骨组织活检、免疫组化及流式细胞学等检查确诊为弥漫大B细胞性PBL。行R-CHOP化疗方案治疗,化疗后症状缓解,但出现CNS浸润。先后给予6次鞘内注射(Ara-C、MTX、DEX),并同时2次大剂量的甲氨蝶呤(HD-MTX)系统性化疗,10次腰骶部放疗后,症状缓解,但3个月后因肺部感染死亡。结论:本例患者以骨痛为首发表现,PET/CT结合MRI示多发骨损害,经骨髓象及活检、免疫组化染色,流式细胞学检查明确诊断,对PBL应重视CNS侵犯及预防。     

Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24553 patients with Hashimoto's disease

There are few large‐scale reports of primary thyroid lymphoma (PTL). This study clinically and pathologically reviewed 171 patients with PTL and 24 553 patients with Hashimoto’s disease at Ito Hospital between January 1990 and December 2004, to investigate the clinical features and the treatment outcomes of PTL. The median age of the patients with PTL was 67 years (range, 27–90 years). The pathological diagnosis of PTL patients included diffuse large B‐cell lymphoma (DLBCL) (n = 74), DLBCL with mucosa‐associated lymphoid tissue (MALT) lymphoma (n = 13), MALT lymphoma (n = 80) and others (n = 4). Of the 167 patients with B‐cell lymphoma, treatment included combined modality therapy (CMT) (n = 95), radiation therapy (RT) alone (n = 60) and chemotherapy alone (n = 6). Information on treatment was not available in six patients. Information on treatment response was available in 154 patients; 149 patients (97%) responded to treatment. According to the institutional treatment strategy of Ito Hospital, 45 of 54 patients with stage IE disease received RT alone, and 87 of 113 stage IIE patients received CMT. The 5‐year overall survival rate was 85% (95% confidence interval, 79–91%). This study demonstrated that PTL showed good response to radiotherapy and chemotherapy and had a favourable prognosis.     

Survival of AIDS‐related diffuse large B‐cell lymphoma,Burkitt lymphoma,and plasmablastic lymphoma in the German HIV Lymphoma Cohort

Overall survival (OS) of patients with acquired immunodeficiency syndrome (AIDS)‐related Burkitt lymphoma (BL), diffuse large B‐cell lymphoma (DLBCL) and plasmablastic lymphoma (PBL) was analysed in the German AIDS‐related‐Lymphoma‐Cohort‐Study. Of 291 patients prospectively included between January 2005 and December 2012, 154 had DLBCL, 103 BL and 34 PBL. Two‐year OS rates were similar between BL (69%) and DLBCL patients (63%) but lower for PBL patients (43%). Intermediate (Hazard ratio [HR] 4·1 95% confidence interval [CI] 1·98–8·49) or high (HR 4·92 95% CI 2·1–11·61) International Prognostic Index, bone marrow involvement (HR 1·69 95% CI 1·00–2·84) and PBL histology (HR 2·24 95% CI 1·24–4·03) were independent predictors of mortality.     

Clinicopathological characteristics and prognostic factors of primary pulmonary lymphoma

BackgroundPrimary pulmonary lymphoma (PPL) is a rare extranodal lymphoma originating from the lung, accounting for 0.5–1.0% of primary lung malignant tumors. Previous case reports or cohort studies included a limited sample size; therefore, the understanding of the disease remains inadequate, and clinical data regarding PPL are limited.MethodsPatients with PPL diagnosed histologically and radiologically between January 2000 and December 2019 at our center were retrospectively analyzed.ResultsIn total, 90 consecutive cases were included in this research. Forty-seven (52.2%) patients were female, and the median age was 54 years old. Non-Hodgkin’s lymphoma (PPNHL) was the most common type of PPL (71/90, 78.9%), and mucosa-associated lymphoid tissue (MALT) lymphoma was the most common pathological subtype of PPNHL (56.3%) followed by diffuse large B-cell lymphoma (DLBCL) (32.4%). Thirty-nine (43.3%) patients underwent surgical treatment, and the others received chemotherapy alone or combined with radiotherapy. The estimated 5-year overall survival (OS) rates of MALT lymphoma and non-MALT lymphoma were 68.9% and 65.9%, respectively. Univariate analysis of PPL showed that clinicopathological features that significantly correlated with worse OS were age over 60 years (P=0.006<0.05), elevated LDH (P=0.029<0.05) and β2-MG (P=0.048<0.05) levels, clinical stage II2E and greater (P=0.015<0.05), and nonsurgical treatment (P=0.046<0.05). Age (P=0.013<0.05) was an independent prognostic factor for the 5-year OS of patients through multivariate analysis.ConclusionsAge over 60 years old, elevated LDH and β2-MG levels, clinical stage II2E disease or higher, and nonsurgical treatment were associated with poor prognosis in patients with PPL. Age can be used as a potential independent prognostic factor for PPL.     

Clinical features,management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)

‘Multifocal bone lymphoma’ or ‘polyostotic lymphoma’ is a neoplasm with exclusive multifocal involvement of the skeleton, without affecting lymph nodes or other soft tissues. Knowledge on this uncommon condition is limited because the related literature is sparse and fragmentary. We reviewed cases of multifocal bone diffuse large B‐cell lymphoma (MB‐DLBCL) registered in a clinico‐pathological database of the International Extranodal Lymphoma Study Group that includes 499 cases of bone lymphoma. Clinical features, management and prognosis of 37 MB‐DLBCL patients and 63 ‘controls’ (stage‐IV DLBCL and skeletal involvement) were analysed. Presentation and treatment of MB‐DLBCL and controls were identical. At a median follow‐up of 52 months (10–189), MB‐DLBCL patients exhibited a significantly better response rate (92% vs. 65%; P = 0·002), progression‐free survival (5‐year: 56 ± 9% vs. 34 ± 6%; P = 0·003) and overall survival (5‐year: 74 ± 8% vs. 36 ± 7%; P = 0·002). Among MB‐DLBCL patients, the use of post‐chemo radiotherapy was associated with better overall survival (5‐year: 83 ± 12% vs. 55 ± 16%; P = 0·003). Two MB‐DLBCL patients (5·4%) with spine and skull involvement experienced central nervous system (CNS) relapse. Thus, MB‐DLBCL patients exhibit a significantly better prognosis compared to patients with advanced‐stage DLBCL, and should be treated with conventional anthracycline‐based chemotherapy, keeping intensified treatment for relapsing cases, considering involved‐field radiotherapy, and CNS prophylaxis in high‐risk patients.     

Plasmablastic lymphoma presenting in a human immunodeficiency virus-negative patient: a case report

Plasmablastic lymphoma (PBL), an aggressive non-Hodgkin's lymphoma that carries a poor prognosis, previously has been identified almost exclusively in patients infected with the human immunodeficiency virus (HIV). We present a case of a 42-year-old HIV-negative patient presenting with an isolated nasal cavity mass, the typical presentation for PBL. The patient was given systemic chemotherapy, central nervous system prophylaxis, and consolidative locoregional radiotherapy and achieved a complete clinical response. This case suggests PBL should be considered in HIV-negative patients with characteristic findings.     

Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma

The identification of immunogenic cancer testis antigens (CTAs) as immunotherapeutic targets represents one approach to improve treatment options for diffuse large B-cell lymphoma (DLBCL). We previously identified PASD1 [PAS (Per ARNT Sim) domain containing 1 (PASD1)], a DLBCL-associated CTA that was expressed in a range of hematopoietic malignancies. The aim of the present study was to investigate the presence of a cytotoxic T-cell (CTL) response to PASD1 in DLBCL patients. A significant γ-interferon (IFN) release was detected in 21/29 HLA-A*0201-positive DLBCL patients (18 de novo DLBCL, two transformed DLBCL and one T-cell rich B-cell lymphoma) following short-term culture of their peripheral blood mononuclear cells stimulated with five HLA-A*0201-restricted PASD1 peptides. No significant responses were detected in 21 HLA-A*0201-negative DLBCL patients (12 de novo DLBCL, seven transformed DLBCL, two T-cell rich B-cell lymphoma) or six normal subjects. CTL cell lines were able to lyse PASD1-positive tumour cells in a major histocompatibility complex-Class I dependent manner. The presence of a γ-IFN response correlated with PASD1 protein expression in the tumour cells in 12/15 cases studied. This is the first report of a CTL response to a CTA in DLBCL. Our results provide additional valuable evidence supporting PASD1 as a potential immunotherapeutic target for the treatment of DLBCL and other malignancies.